Samso News: Control Bionics Limited – Strategic Joint Venture to Expand iOS Speech-Generating Devices in the United States - A Cash Printing Business.
- Noel Ong
- 1 day ago
- 7 min read
This summary reflects the factual disclosures made in the ASX release dated 26 February 2026 below:
Joint venture with NextLevel Assistive Technology – 26 February 2026 ( view the announcement )
Control Bionics Limited (ASX: CBL) operates in the neurotechnology medical device sector, with more than 20 years of experience in surface electromyography (EMG) technologies. The Company develops assistive communication solutions for individuals with complex communication needs.
The ASX announcement dated 26 February 2026 outlines a strategic joint venture with NextLevel Assistive Technology to expand Control Bionics’ presence in the United States iOS-based speech-generating device (SGD) market.
The United States represents the largest global Augmentative and Assistive Communication (AAC) market, with an estimated 2.5–3.5 million individuals requiring speech-generating solutions. This release provides structural detail on how Control Bionics intends to participate in that segment through a capital-light partnership model.
About NextLevel Assistive Technology
NextLevel Assistive Technology is a United States-based developer of speech-generating device (SGD) hardware designs focused on Apple iOS-based Augmentative and Assistive Communication (AAC) solutions.
The company specialises in designing device chassis and hardware components that integrate with iOS tablets to create dedicated speech-generating devices for individuals with complex communication needs. These devices are typically used by people with neurological conditions such as ALS, cerebral palsy, stroke-related impairments and other conditions that affect speech.
Introduction – Joint Venture to Enter High-Volume iOS-Based AAC Segment in the US
Control Bionics Limited announced that its US subsidiary, Control Bionics Inc., has entered into an exclusive manufacturing, distribution and intellectual property licence agreement with NextLevel Assistive Technology.
The agreement is structured to jointly commercialise a new range of iOS-based speech-generating devices under the Uno Touch Omni and Active product line in the United States.
The structure is capital light. NextLevel will fund all device tooling and manufacturing. Control Bionics will perform final assembly, regulatory compliance and distribution.
Highlights – Exclusive iOS-Based SGD Agreement in the US Market
The key elements of the agreement are:
Exclusive agreement to manufacture, distribute and sell UnoTouch Omni and Active iOS-based SGDs in the United States
Control Bionics to act as FDA Manufacturer of Record and distributor through established partner channels
NextLevel to fund all device tooling and manufacturing
Control Bionics to receive a fixed per device contribution margin
Advanced negotiations with multiple US distributors under non-binding Letters of Intent
Capital-light structure with positive working capital dynamics
Industry estimates referenced in the announcement indicate:
Approximately 60–70% of new US SGD prescriptions are tablet-based
Annual US SGD volumes of approximately 55,000–65,000 devices
iOS-based SGDs represent a US$100–150 million annual segment
The Company disclosed that negotiations with distributors contemplate potential annual volumes in the range of approximately 1,000–1,500 iOS devices. These volumes are subject to definitive agreements, regulatory and reimbursement processes, and market rollout. There is no certainty that negotiations will result in binding agreements or that contemplated volumes will be realised.
Management Commentary
The CEO stated that the partnership allows Control Bionics to participate at scale in the largest segment of the US AAC market through existing distributor channels, without capital investment or manufacturing risk.
The announcement states that the arrangement is revenue, profit and cashflow accretive. It complements the NeuroNode neural-interface platform by adding a high-volume iOS device portfolio, strengthening the Company’s position within US distribution channels.
The Business of Control Bionics Limited – Company Context
Control Bionics is a neurotechnology medical device company focused on assistive communication solutions. Its core patented NeuroNode technology detects EMG signals from skeletal muscles and enables speech and computer-controlled functions.
The NeuroNode integrates touch, eye gaze and neural interface control, providing multi-modal access for users.
The Company is also commercialising NeuroStrip, a miniaturised wearable EMG device that may provide access to additional markets including diagnostics, sports performance and rehabilitation.
Control Bionics operates in North America, Australia, Europe and Japan.
Previous Samso News Coverage
Published 13 February 2026 - Control Bionics Limited — U.S. Pilot Distribution Agreement with Tobii Dynavox
Near-Term Milestones to Watch
Execution of definitive agreements with US distributors
Completion of regulatory and reimbursement processes
Initial commercial rollout of UnoTouch Omni and Active devices
Confirmation of annual unit volumes within the contemplated 1,000–1,500 device range
Integration of iOS-based portfolio alongside the NeuroNode product suite
Samso Concluding Comments
The ability to communicate is a critical aspect of the human species. It is what makes us as an evolved and evolving species. Control Bionics devices empower those who fall behind in the race to have a moral functional daily life.
The paragraphs below gives potential investors a good feel of what is to be gained for the shareholders if the company can get the application and the execution on track.
Our devices empower people across a wide spectrum of needs, from those living with conditions such as ALS/MND, Spinal Muscular Atrophy, Cerebral Palsy, and Spinal Cord Injury, to athletes and patients working on sports performance and physical rehabilitation.
When diagnosed or recovering, you are making a lot of tough decisions. When it comes to augmentative and alternative communication devices (AAC) and wearable neurotechnology, the decision is easy. Control Bionics guides you through every step of the process and makes sure you receive the technology you need to communicate, recover, and perform at your best all day, every day.
----- Control Bionics Limited
This announcement outlines a defined expansion into the tablet-based segment of the US speech-generating device market. The agreement divides roles between NextLevel and Control Bionics, separating manufacturing funding from regulatory and distribution functions.
Getting the business into the US AAC market data will allow the company to get some form of footing and this opportunity presented indicates a structural shift toward tablet-based devices. The joint venture aligns the Company with this high-volume segment while maintaining its existing neural-interface product line.
The capital-light model reduces direct manufacturing exposure. NextLevel funds tooling and chassis production, while Control Bionics retains regulatory responsibility and distribution control as FDA Manufacturer of Record.
Distributor negotiations remain non-binding and subject to further agreements, regulatory processes and market rollout. Realisation of contemplated volumes will depend on execution and commercial uptake. If there was a weakness in the ASX release, it would be the non-binding nature as we all know, business strategies need structure. Non-binding agreements can be more show than walk, so lets see how this pans out.
Market Implication - The Investor Lens
Control Bionics are still at an early stage of their journey and the market capitalisation of AUD $24.2M as of 2nd March 2026 is a reflection of the early stage business. Samso has made many comments of the years that we believe that a good health story is far more valuable than a metal discovery, as it has benefits in terms of a financial gain for investors and a more important gain for humanity.
Figure 1: The share price chart for Control Bionics Limited as of the 2nd march 2026. (source: commsec).
This may all sound a bit altruistic but for Samso, making money empathically is a lot more fun than not. The need to enjoy and being purposeful in our investments is more meaningful and satisfying. Our interest in following CBL is to be part of seeing the business do well and like all investments of this nature, patience is the only medicine.
The Samso Way – Seek the Research
Here at Samso, we pride ourselves on delivering content for investors that is independent and informed by over three decades of experience in the industry. Our content is well-researched and is only created if I see merit in discussing the company's story.
Our mission is simple: cut through the noise and spotlight what matters—genuine stories, grounded insights, and real opportunity.
Our content is well-researched and is only created if the team sees merit in discussing the company or concept. Investors can explore our three core platforms:
There may be numerous paths to success in investing, but the common thread among successful individuals is that they remain committed to making informed decisions. Equip yourself with the right knowledge and tools, and you will be well on your way to achieving your financial goals.
Most importantly, investors need to be absolutely diligent in understanding their own risk-reward tolerance and capabilities. Never bite off more than you can chew. As they say, Rome wasn’t built in a day, and the Great Wall stood because it took centuries to complete.
The Samso Philosophy:
Stay curious. Stay sharp. And remember—digging deeper always uncovers the real value.
In Life, there is no such thing as a Free Lunch.
Never bite off more than you can chew is my parting comment.
Happy Investing, and the only four-letter word you need to know is DYOR.
To support our independent nature of our work, please head over to our Support Page and give us a helping hand in any of the ways listed. This is a new initiate for the Samso Platform, and it was always the concept of Samso when we started this journey in 2018.
Disclaimer
The information or opinions provided herein do not constitute investment advice, an offer, or solicitation to subscribe for, purchase, or sell the investment product(s) mentioned herein. It does not take into consideration, nor have any regard to your specific investment objectives, financial situation, risk profile, tax position and particular, or unique needs and constraints.
Share to Grow: Your Bonus
Samso has just released an eBook: How to Add Value to your Share Portfolio
A lesson on geological models sought by mining companies that gives insight and an understanding of which portfolios are better - and potentially more lucrative – investments. Click here to download this eBook.
If you find this article informative and useful, please help me share the information. I try to write about topics that are interesting and have the potential to be of investment value. It is not easy to find stories that fit those parameters. If you or your organisation sees the benefit of what Samso is trying to achieve and has a need to share your journey, please contact me at noel.ong@samso.com.au.
Samso is a trusted platform that equips dedicated investors with up-to-date industry knowledge and insights from top CEOs and thought leaders. By staying informed on business advancements and market trends, investors can enhance their financial decisions through a combination of expert guidance and their own research.
Comments